• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » MassDevice On Call: Scientists work towards a botanical-based nasal spray for TBI

MassDevice On Call: Scientists work towards a botanical-based nasal spray for TBI

December 3, 2010 By MassDevice

MassDevice On Call

Scientists work towards a botanical-based nasal spray for TBI. Evidence from cell culture and animal models suggests that huperzine A — a moss-derived botanical used in traditional Chinese medicine to treat swelling, fever, inflammation, blood disorders and schizophrenia — might dampen down the body’s physiological response to traumatic brain injury, which causes subsequent damage to the victim’s brain, writes Children’s Hospital Boston’s Vector Blog.

Bird flu is back. Officials in Japan and Hong Kong confirm reports of bird flu in chickens and a human, respectively, reports The Wall Street Journal.

FDA reports record low in new drug applications, approvals down 32 percent. The Food & Drug Administration has said it expects 118 new drug applications by the end of 2010, a new low and down from 140 in 2009. The number of new drugs approved by the agency is down 32 percent from last year, according to amednews.

Merck to buy insulin developer SmartCells. With an eye on remaining one of the leaders in the diabetes field, Merck (NYSE:MRK) has agreed to pay more than $500 million to acquire SmartCells, a Beverly, Mass.-based biotech with some intriguing insulin technology that originated at MIT. The company did not take any venture funding, according to Xconomy Boston.

FDA warns Invisalign maker on improper reporting of side effects. Align Technology disclosed on Nov. 30 that it received a warning letter from the Food & Drug Administration on Nov. 18 and that the company has since provided the watchdog agency with information it believes will resolve the matter, reports the San Jose Mercury News.

Who’s living with less? While questioning each other’s money-making techniques, the chiefs of Massachusetts’ most prominent hospital network and private health insurer agreed that controlling soaring healthcare costs begins with a shift in thinking: adjust to a climate of limited resources and learn to live with less, reports MetroWest Daily News.

Hospital perks: Are they worth the cost? As healthcare reform moves forward, we need to decide whether hospital amenities like hotel-style room service, massage therapy and magnificent views are worth their cost, according to a perspective in the New England Journal of Medicine.

A pearl of a COPD therapy. Pearl Therapeutics bagged a $69 million venture round last month, and now its clear why. The Redwood City, California, biotech has clinical trial results that show its inhalable drug for chronic obstructive pulmonary disease works better than standard Tiotropium (Spiriva), a $3 billion annual seller for Pfizer and Boehringer Ingelheim, reports Xconomy San Francisco.

M&A the hot ticket in med devices. From Medtronic’s (NYSE:MDT) deal to buy Ardian for $800 million to Stryker’s (NYSE:SYK) agreement to buy Boston Scientific’s (NYSE:BSX) neurovascular business for $1.5 billion, mergers and acquisitions are picking up in the medical device industry, Reuters reports.

Asthmatx device holds $443.5M of promise. And how promising is Asthmatx Inc.’s device to treat patients with severe asthma? Up to $443.5 million-worth, based on how much Boston Scientific is willing to pay for the Sunnyvale, California, company if it hits revenue targets laid out in its acquisition deal, according to the Silicon Valley/San Jose Business Journal.

Material from MedCity News was used in this report.

Filed Under: Business/Financial News, News Well

More recent news

  • Neuronetics names Steven Pfanstiel chief financial officer
  • Medtronic to distribute Future Medical’s peripheral guidewires
  • AtriCure completes enrollment in stroke prevention trial
  • GT Medical raises $53M to support brain tumor treatment
  • Imperative Care, Proximie partner to develop surgical robot to treat stroke

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy